Non-adherence to ivermectin in onchocerciasis-endemic communities with persistent infection in the Bono Region of Ghana: a mixed-methods study
-
Published:2023-11-16
Issue:1
Volume:23
Page:
-
ISSN:1471-2334
-
Container-title:BMC Infectious Diseases
-
language:en
-
Short-container-title:BMC Infect Dis
Author:
Otabil Kenneth Bentum,Basáñez María-Gloria,Ankrah Blessing,Bart-Plange Emmanuel John,Babae Theophilus Nti,Kudzordzi Prince-Charles,Darko Vera Achiaa,Raji Abdul Sakibu,Datsa Lydia,Boakye Andrews Agyapong,Yeboah Michael Tawiah,Fodjo Joseph Nelson Siewe,Schallig Henk D. F. H.,Colebunders Robert
Abstract
Abstract
Background
The World Health Organization has proposed that onchocerciasis elimination (interruption) of transmission be verified in 12 (approximately a third) endemic countries by 2030. The strategy to reach this goal is based on ivermectin Mass Drug Administration (MDA) with high geographical and therapeutic coverage. In addition to coverage, high levels of treatment adherence are paramount. We investigated factors associated with ivermectin intake in an area of Ghana with persistent Onchocerca volvulus infection.
Methods
In August 2021, a cross-sectional mixed-methods study was conducted in 13 onchocerciasis-endemic communities in the Bono Region of Ghana. Individuals aged ≥ 10 years were invited to participate in a questionnaire survey. A total of 48 focus group discussions and in-depth interviews with 10 community drug distributors and 13 community leaders were conducted.
Results
A total of 510 people participated in the study [median age: 32, interquartile range 30 (20‒50) years]; 274 (53.7%) were females. Of the total, 320 (62.7%) declared that they adhered to each treatment round and 190 (37.3%) admitted they had not taken ivermectin during at least one MDA round, since becoming eligible for treatment. Of 483 participants with complete information, 139 (28.8%) did not take ivermectin during the last round (March 2021), and 24 (5.0%) had never taken ivermectin (systematic non-adherers). Reasons for not taking ivermectin included previous experience/fear of side-effects, being absent during MDA, pregnancy, the desire to drink alcohol, and drug distribution challenges. Being male, having good knowledge and perception of the disease, and not having secondary or higher level of formal education were significantly associated with higher odds of ivermectin intake.
Conclusions
A relatively high level of non-adherence to ivermectin treatment was documented. There is a need for targeted educational and behavioural change campaigns to reverse these trends and ensure a steady course toward meeting onchocerciasis elimination targets in Ghana.
Funder
United States Agency for International Development
UK Medical Research Council and UK Foreign, Commonwealth & Development Office
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases
Reference51 articles.
1. Duke BOL. Human onchocerciasis—an overview of the Disease. Acta Leiden. 1990;59:9–24.
2. World Health Organization. Onchocerciasis. Key facts. 2022. Available from: https://www.who.int/news-room/fact-sheets/detail/onchocerciasis. [Accessed 12 September 2023].
3. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019, Lancet. 2020;396 (10258):1204–22. Onchocerciasis—Level 3 cause. Available from: https://www.thelancet.com/pb-assets/Lancet/gbd/summaries/diseases/onchocerciasis.pdf. [Accessed 12 September 2023].
4. Ghana Health Service. Ghana NTD Master Plan 2016–2020. Expanded Special Project for Elimination of Neglected Tropical Diseases. 2020. Available from: https://espen.afro.who.int/system/files/content/resources/GHANA_NTD_Master_Plan_2016_2020.pdf. [Accessed 12 September 2023].
5. Otabil KB, Ankrah B, Bart-Plange EJ, Donkoh ES, Avarikame FA, Ofori-Appiah FO, et al. Prevalence of epilepsy in the onchocerciasis endemic middle belt of Ghana after 27 years of mass drug administration with ivermectin. Infect Dis Poverty. 2023;12(1):75.